Oral or intranasal administration of vaccines remains the only economically feasible approach to mass immunization of humans on a global scale. To date, however, only a few vaccines are available for administration by these routes. A promising avenue to expanding the range of oral vaccines involves the use of food staples as a vector. Indeed, there are several reports on engineered plants that produce biomedically important substances (1-7) and one report on human ingestion of transgenic raw potatoes expressing Escherichia coli enterotoxin (8). We obtained transgenic lupin callus to express hepatitis B virus (HBV) surface antigen (HBsAg), which was fed to mice. Mice fed the transgenic lupin tissue developed significant levels of HBsAg-specific antibodies. Based on the encouraging results of animal studies, we obtained transgenic lettuce plants expressing HBsAg for human consumption. The high HBsAg-specific immunoglobulin G (IgG) response of human volunteers in this study point to the future of active immunization using dietary staples.
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Transgenic lines of lupin callus and lettuce were obtained using Agrobacterium tumefaciens C58 (pROK2S) and A. tumefaciens L4404 (pROK2S), respectively. The lines of transgenic lupin (callus) and lettuce (plants) in which the presence of HBsAg was confirmed by polymerase chain reaction (data no shown) were further analyzed for the accumulation of HbsAg, as determined in tissue extracts from the transgenic lines (Fig. 1) . The estimated antigen content varied considerably in individual lines of both transgenic lupin and lettuce leaves (from 11 ng/g in line LL-7 to 150 ng/g of fresh weight in line LL-10 of lupin callus and from 1 ng/g in line LT1 to 5. 5 ng/g in line LT-5 of fresh weight in transgenic lettuce).
Callus tissue from the LL-10 line was used for oral immunization of mice. In group A mice (see Materials and Methods), the second dose of lupin callus elicited an HBsAg-specific IgG response that was up to twofold higher than that observed in the sera of control mice (OD 0.36 vs. 0.15, Pϭ0.0015) ( Fig. 2A) . Sera from mice fed with transgenic callus over 5 consecutive days at 1 g per day showed no significant HBsAg-specific antibody response after two feedings as compared with sera from mice fed the control callus (Fig. 2B) . Based on these results, human volunteers were fed HBsAg-expressing transgenic lettuce leaves twice: first 200 g, and within 2 months, 150 g. Analysis of sera obtained from human volunteers 2 and 4 wk after the first ingestion of HBsAgexpressing lettuce revealed no significant levels of HBsAg-specific IgG (Fig. 3) . However, 2 wk after the second feeding, sera from all three volunteers showed HBsAg-specific antibody titers above 3 IU/l and sera from two of these volunteers had an HBsAgspecific antibody level higher than 10 IU/l, accepted as a minimum protective level against HBV. Four weeks after the second ingestion, HBsAg-specific antibody levels declined (1.7 IU/l, Fig. 3 ), although no further decline was observed by 12 wk (Fig. 3) . Serum IgA production was not detected. No noticeable side effects were observed in the volunteers who ingested transgenic lettuce expressing HBsAg during 20 wk after first ingestion.
The present study shows that antigens expressed in plants administered orally can induce a specific anti-HBsAg antibody response in mice as well as in humans. Mice that received 5 g of transgenic lupin callus over the course of 1 day developed a better immune response to HBV than those fed in multiple doses of 1 g of the tissue.
Two of the three human volunteers mounted a significant immune response after a second ingestion of transgenic lettuce. It remains unclear why one of the three volunteers did not develop a significant HBV response to the orally administered HBsAg. Vaccination of this subject with a standard HBV vaccine may clarify whether he is capable of developing significant immune response to HBV antigen at all. At 4 wk after the second ingestion of transgenic lettuce, serum HBsAg-specific antibody levels in all three volunteers had decreased considerably, although no further decline was observed at 12 wk Further monitoring of the HBV-specific antibody levels in these three subjects may provide additional information about the nature of the immune response and about the potential need for multiple feedings of transgenic plant-based vaccine.
One of the concerns regarding the plant-derived edible vaccines was related to the fact that humans ingesting transgenic plant expressing a foreign gene may not respond to immunization because the same species of plants are part of their regular diet. The results of this study suggest that an immune response against HBsAg can be elicited by ingestion of transgenic lettuce in humans who are consuming nontransgenic lettuce in their diet.
Two of three human volunteers who ingested transgenic lettuce leaves expressing HBsAg developed a serum antibody response at levels considered protective, thus suggesting that humans may be immunized orally against HBV with plants expressing the viral antigen.
MATERIALS AND METHODS

DNA cloning
All enzymatic digestions, ligations, cell transformations, and other manipulations with DNA were done according to Sambrook et al. (9) . Plasmid pROK was used as a shuttle vector to incorporate HBsAg coding sequences into the Ti-plasmid of A. tumefaciens. HBsAg was cloned from pHB614 containing the full genome of HBV adw subtype in order to obtain pROK2S (Fig. 4) . Plasmid pROK2S carrying the HBsAg coding sequence was electroporated (10) into A. tumefaciens strains C58 and LBA4404 (10).
Plant transformation
Four-day-old seedlings of yellow lupin (Lupinus luteus L.) were used as primary explants. After removing the distal parts, cotyledons were transformed using A. tumefaciens C58 (pROK2S). After 2 days of cultivation on antibiotic-free, modified Murashige-Skoog medium (T. Pniewski, J. Kapusta, and A. B. Legocki, unpublished results), the explants were transferred to special medium (11) to stimulate callus growth. Cotyledons isolated from 2-day-old seedlings of lettuce (Lactuca sativa L.) cv. Burpee Bibb were inoculated with A. tumefaciens LBA4404 (pROK2S). Transgenic lettuce plants were obtained as described (11) .
Protein extraction and analysis
Protein was extracted as described (2) from transgenic tissue homogenized in phosphate buffer. The homogenate was centrifuged at 30,000 ϫ g for 15 min to remove nonhomogenized cell debris. HBsAg in the supernatant was quantitated using an Auszyme monoclonal diagnostic kit (Abbott Lab., North Chicago, Ill.) according to the manufacturer's instructions. The amount of antigen in plant extracts was calculated using a standard curve based on different concentrations of purified HBsAg.
Immunization of mice
Six-to 8-wk-old male BALB/c mice (five in a group) were immunized by feeding with transgenic lupin callus containing HBsAg. Group A mice received 5 g of callus tissue for 1 day, and group B mice were fed 1 g of callus on each of 5 consecutive days; the respective feeding protocols were repeated once after a 1 month interval. Callus tissue fed to each mouse was equivalent to ϳ750 ng of HBsAg. Transgenic callus was administrated without any additional feeding. Control mice were fed with transgenic callus containing vector without HBsAg, using the same schedule of administration. Serum samples were collected at the following times: 2 days before the first feeding (preimmune) from all the mice; 2 wk after the first and second administrations for mice receiving
Immunization of human volunteers
Five adult volunteers (male and female), 25-59 years of age and in good health, were enrolled in the study after signing consent forms. The volunteers had no previous HBV vaccination, no history of HBV infection, and no detectable anti-HBs or anti-HBc serum antibodies. Three individuals received transgenic lettuce leaves twice: 200 g at first, and within 2 month, 150 g. The amount of HBsAg in the lettuce plants varied from 0.1 to 0.5 g/100 g of fresh tissue. Two control individuals were given the same amount of nontransgenic lettuce according to the same schedule. Volunteers consumed no food or liquids for 1 h before and after ingesting lettuce. Leaves were washed and were eaten without additives. Blood samples from all volunteers were collected before the first ingestion (preimmune), 2 and 4 wk after the first ingestion, and 2, 4, and 12 wk after the second lettuce ingestion.
ELISA
Mouse and human serum samples were analyzed for the presence of anti-HBsAg-specific antibodies by enzyme-linked immunoabsorbent assay (ELISA), as described (12), using 96-well plates (Nunc-Immuno PolySorp, Roskilde, Denmark) coated with 100 l per well of HBsAg (2 g/ml, Biodesign, Kennebunkport, Maine) overnight at 4°C. Peroxidase-conjugated goat anti-mouse IgG (␥-chain-specific, Sigma, St. Louis, Mo.) and IgA (␣ chain-specific, Sigma) were used to detect anti-HBsAg-specific antibodies in sera from immunized mice. Anti-HBsAg-specific antibodies in human sera were detected using peroxidase-conjugated goat anti-human IgG (␥-chain specific, Sigma) and IgA (␣ chain specific, Sigma).
The Hepanostika anti-HBs diagnostic kit (Organon Teknika) was used to estimate the level of antibodies in human sera. The assay was carried out according to the diagnostic kit protocol and the instructions for Organon Teknika Microelisa Comp system. The concentration of antiHBsAg antibody in the test sera was calculated using WHO standardized sera provided by the manufacturer. One of the standard serum samples contained no anti-HBsAg antibodies. Two others had anti-HBsAg antibody titers equal to 10 IU/l (low positive control) and 100 IU/l (high positive control). 
